Teleflex Advances Freesolve Resorbable Heart Scaffold in Head‑to‑Head Trial With Market‑Leading Stent
Teleflex (TFX) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Teleflex (TFX) is running a new clinical study titled “Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries.” The goal is to see if its Freesolve resorbable magnesium scaffold is as safe and effective as a leading drug‑eluting stent, which could be important for long‑term heart care options.
The study tests two heart devices used to open blocked coronary arteries. One is Teleflex’s Freesolve resorbable magnesium scaffold, designed to support the artery and then gradually dissolve, and the other is Abbott’s Xience drug‑eluting stent, a standard metal stent that stays in the vessel.
This is an interventional trial where patients are randomly assigned to either Freesolve or Xience, so the comparison is more reliable for investors tracking efficacy and safety. The study uses a single‑blind design, meaning patients do not know which device they receive, and the main goal is treatment of coronary artery disease in a real‑world setting.
The trial was first submitted in November 2025, marking the formal start of the clinical process for this scaffold system. The most recent update was filed on June 15, 2026, signaling that Teleflex is actively managing the program and that the trial is still recruiting and progressing.
For investors, this update highlights Teleflex’s push into next‑generation resorbable coronary devices, an area with strategic value if outcomes match or beat current market leaders. Positive future data could support multiple expansion for TFX and pressure rivals in drug‑eluting stents such as Abbott and Boston Scientific, though clinical and regulatory risks remain until results are posted.
The study remains active and updated on ClinicalTrials.gov, where investors can find further details as new information is released.
